Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time

European Journal of Pharmacology

Volumn 352, Issue 1, 1998, Pages 59-63

  Sato, Kazuo ^a,b   Kaku, Seiji ^a   Hirayama, Fukushi ^a   Koshio, Hiroyuki ^a   Matsumoto, Yuzo ^a   Kawasaki, Tomihisa ^a   Iizumi, Yuichi ^a  

^a Inst for Drug Discovery Research   (Japan)

^b Cardiovascular Diseases Research   (Japan)

Author keywords

Bleeding time; Factor Xa inhibitor; Oral anticoagulant; Venous thrombosis; Warfarin; YM 75466

Indexed keywords

[N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID MONOMETHANE SULFATE; ANTICOAGULANT AGENT; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; DOSE RESPONSE; DRUG EFFECT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; THROMBOPLASTIN; WARFARIN;

EID: 0031823861     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00339-2     Document Type: Article

References (19)

1. Berndt, M.C., Gregory, C., Dowden, G., Castaldi, P.A., 1986. Thrombin interactions with platelet membrane proteins. Ann. NY. Acad. Sci. 485, 374-386.
2. Elódi, S., Varadi, K., 1979. Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation. Thromb. Res. 15, 617-629.
3. Freund, M., Cazenave, J.P., Courtney, M., Degryse, E., Roitsch, C., Bernat, A., Delebassee, D., Defreyn, G., Maffrand, J.P., 1990. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb. Haemost. 63, 187-192.
4. Hara, T., Yokoyama, A., Tanabe, K., Ishihara, H., Iwamoto, M., 1995. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74, 635-639.
5. Harder, S., Thurmann, P., 1996. Clinically important drug interactions with anticoagulants. An update. Clin. Pharmacokinet. 30, 416-444.
6. Hérault, J.P., Bernat, A., Pflieger, A.M., Lormeau, J.C., Herbert, J.M., 1997. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J. Pharmacol. Exp. Ther. 283, 16-22.
7. Herbert, J.M., Bernat, A., Maffrand, J.P., 1992. Importance of platelets in experimental venous thrombosis in the rat. Blood 80, 2281-2286.
8. Herbert, J.M., Bernat, A., Dol, F., Herault, J.P., Crepon, B., Lormeau, J.C., 1996. DX-9065a a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 276, 1030-1038.
9. Higgins, D.L., Lewis, S.D., Shafer, J.A., 1983. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J. Biol. Chem. 258, 9276-9282.
10. Hirsh, J., 1991. Oral anticoagulant drugs. N. Engl. J. Med. 324, 1865-1875.
11. Lefkovits, J., Topol, E.J., 1994. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90, 1522-1536.
12. Neeper, M.P., Waxman, L., Smith, D.E., Schulman, C.A., Sardana, M., Ellis, R.W., Schaffer, L.W., Siegl, P.K., Vlasuk, G.P., 1990. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. J. Biol. Chem. 265, 17746-17752.
13. Rosenberg, J.S., Beeler, D.L., Rosenberg, R.D., 1975. Activation of human prothrombin by highly purified human factors V and Xa in presence of human antithrombin. J. Biol. Chem. 250, 1607-1617.
14. Sato, K., Kawasaki, T., Taniuchi, Y., Hirayama, F., Koshio, H., Matsumoto, Y., 1997. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur. J. Pharmacol. 339, 141-146.
15. Sato, K., Kawasaki, T., Hisamichi, N., Taniuchi, Y., Hirayama, F., Koshio, H., Matsumoto, Y., 1998. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. Pharmacol. 123, 92-96.
16. Schaffer, L.W., Davidson, J.T., Vlasuk, G.P., Dunwiddie, C.T., Siegl, P.K., 1992. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler. Thromb. 12, 879-885.
17. Talbot, M.D., Ambler, J., Butler, K.D., Findlay, V.S., Mitchell, K.A., Peters, R.F., Tweed, M.F., Wallis, R.B., 1989. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb. Haemost. 61, 77-80.
18. Taniuchi, Y., Sakai, Y., Hisamichi, N., Kayama, M., Mano, Y., Sato, K., Hirayama, F., Koshio, H., Matsumoto, Y., Kawasaki, T., 1998. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb. Haemost., in press.
19. Wells, P.S., Holbrook, A.M., Crowther, N.R., Hirsh, J., 1994. Interaction of warfarin with drugs and food. Ann. Intern. Med. 121, 676-683.